Browse by ▼

Medtronic, Inc.

  • The Best In An Expensive Sector

    By Matthew Frankel - May 13, 2013 | Tickers: BAX, BDX, MDT

    Medtronic Inc. (NYSE: MDT) is one of the leading manufacturers of equipment for the health care industry.  In fact, the company has a leading market share in several categories, including pacemakers, defibrillators, and diabetes products just to name a few.  The company has grown its revenues tremendously over the past decade (see below), with sales up each and every year, including the entire tumultuous 2008-2010 period.  How many other health more »

  • These Healthcare Stocks Pay Fast-Growing Dividends

    By Aubrey Tabuga - May 11, 2013 | Tickers: MDT, UNH, WLP

    Given the huge potential of the healthcare industry, it is very tempting to peer through it for possible options if one seeks for the best places to earn dividend income. These stocks pay some of the fastest-growing dividends. I say, it is the best time to take advantage of the immense possibilities in this sector. Do check these out.

    Health Insurance Leader

    With 13.6% of the market share in more »

  • Building a Stronger Core With Abbott Laboratories

    By Justin Carley - April 30, 2013 | Tickers: ABT, ABBV, MJN, MDT, RHHBY

    It has been more than a 100 days since Abbott Laboratories (NYSE: ABT) separated its research-based pharmaceutical business into a newly formed entity named AbbVie (NYSE: ABBV). As is often the case, the spin-off has been the initial winner. AbbVie has produced a total return of more than 32% in pretty quick order. Abbott has done well, but the 17% return has clearly not kept pace. AbbVie is now a more »

  • Bright Outlook for Device Makers

    By Ted Cooper - April 28, 2013 | Tickers: BSX, MDT, STJ | Editor's Choice

    In my last article, I argued that Medtronic (NYSE: MDT), Boston Scientific (NYSE: BSX), and St. Jude Medical (NYSE: STJ) were potentially-attractive investments. However, I made a key assumption in the article that is undoubtedly false: I assumed that each company's operations will stay the exact same from now into eternity.

    Although the assumption is false, it is a useful starting point for further analysis. The goal of this more »

  • Obamacare Uncertainty Presents Opportunity

    By Ted Cooper - April 26, 2013 | Tickers: BSX, MDT, STJ

    Health care companies have been caught in a state of limbo since the passage of Obamacare. The market is still sorting out who wins and who loses from the landmark health care overhaul. Meanwhile, Congress has plans to repeal or amend parts of the law. All of this leads to uncertainty about these companies' futures. However, the market's indecisiveness poses as an opportunity for enterprising investors to scoop up more »

  • "The Most Sustainable Company in the World"

    By Tyler Wofford - April 25, 2013 | Tickers: BMY, LLY, MDT, NVO

    In January of 2012, Business Magazine released a list of the most sustainable companies in the world. You might be surprised to see who topped their list. I was surprised that it wasn't a company like Apple, but rather a company in the pharmaceutical industry. As a type 1 diabetic, I understand the costs that go along with the disease. However, even I was surprised to see a company more »

  • Should You Buy Abbott Labs?

    By Zain Abbas - April 18, 2013 | Tickers: ABT, JNJ, MDT

    The earnings season is on the go and couple of pharma players have already announced their quarterly results. Let's have a look at them.

    Abbott Laboratories (NYSE: ABT)reported its quarterly earnings on April 17. The  company posted a revenue of $5.38 billion, short of analysts' estimates of $5.42 billion and 1.8% higher than the revenue for the same period last year. The EPS was reported more »

  • St. Jude Medical news raises investors’ heartbeat

    By Shas Dey - April 15, 2013 | Tickers: BSX, MDT, STJ

    Exciting news came out for St. Jude Medical (NYSE: STJ) shareholders as the company announced that its product, the AMPLATZER Cardiac Plug (ACP), was going into a key phase of clinical trial testing. The ACP is used for the prevention of stroke and the clinical trial is being conducted to demonstrate whether the ACP device is both able and safe to prevent blood clots from travelling out of the left more »

  • Should you Buy Abbott Labs?

    By Zain Abbas - April 15, 2013 | Tickers: ABT, JNJ, MDT

    Abbott Laboratories (NYSE: ABT)

    Abbott Labs is expected to announce its quarterly earnings on April 17. The Street expects the company to post a revenue of $5.42 billion, which will be 3.6% higher than the revenue for the same period last year. The EPS is expected to be $0.41, which lies within the range of $0.40-$0.42 guided by the company.

    The gross margin is more »

  • Buying the Boston Boom

    By Marshall Hargrave - April 14, 2013 | Tickers: ABT, BSX, MDT, STJ

    Boston Scientific (NYSE: BSX) has rallied nicely year to date, up over 35%, but is there still room to grow for this heart-related devices company? Cardiovascular disease remains the number one killer worldwide. The number of adults diagnosed with heart disease in the U.S. is around 11.8 percent of the total population. 
     
    Earlier this year Boston revised growth plans to better account for the challenging economic environment. Boston more »

  • Are These 2 Medical Device Stocks Cheap For A Reason?

    By Joseph Harry - April 12, 2013 | Tickers: BDX, JNJ, MDT

    With the market currently flirting with new highs, and every dip seemingly being bought up, I am continually searching for bargains. Energy and some "big tech" names look somewhat attractive, valuation-wise at least, but I've already got enough of those kinds of stocks.

    Then I found a couple of medical-device makers that appear to be trading at a discount to the overall market. With the Dow sporting a P more »

  • Are These 2 Medical Device Stocks Cheap For A Reason?

    By Joseph Harry - April 9, 2013 | Tickers: BDX, JNJ, MDT

    With the market currently flirting with new highs, and every dip seemingly being bought up, I am continually searching for bargains. Energy and some "big tech" names look somewhat attractive, valuation wise at least, but I've already got enough of those kind of stocks. Then I found a couple of medical device makers, who appear to be trading at a discount to the overall market. With the Dow sporting more »

  • Buybacks Could Keep Up This Stock's Momentum

    By Mike Thiessen - April 2, 2013 | Tickers: COV, MDT, PFE

    Dublin-based pharmaceutical and medical device company Covidien (NYSE: COV) recently announced that it had authorized a share buyback program that could be worth up to $2 billion. This announcement comes just a few months after the company boosted its dividend by more than 15 percent and issued several quarters of solid earnings. To make matters even more interesting, the company appears to be nearing the completion of its long-awaited spin-off more »

  • Prem Watsa Is Buying Into This Small-Cap Stock, Should You Follow?

    By Anh HOANG - March 25, 2013 | Tickers: BSX, MDT, NVDQ

    Recently, Prem Watsa, who is well known as “Canada’s Warren Buffett”, increased his stake significantly in the Canadian medical imaging and therapeutic device company, Novadaq Technologies (NASDAQ: NVDQ). He first initiated a long position in the company in the fourth quarter of 2012, and then he added more in the middle of February, to own nearly 2.84 million shares in the company. Should we follow Prem Watsa into more »

  • Medtronics vs. Obamacare: A Fight to Remember

    By Kyle Dickinson - March 21, 2013 | Tickers: BSX, MDT

    I'm a college student. One day my professor began discussing the new 2.3% excise tax on medical devices caused by the Patient Protection and Affordability Care Act (otherwise known as Obamacare). Much to my surprise (and probably the professor's) the other students in the class were really engaged in the discussion. They were asking questions like, "Does the government have the power to impose this tax," and more »

  • Edwards Lifesciences: A Strong Buy on Recent Dip

    By Palwasha Saaim - March 20, 2013 | Tickers: EW, MDT, STJ

    Back in October, when Edwards Lifesciences (NYSE: EW) missed earnings forecasts and the stock plummeted to its lowest in 10 years, I rated it a buy. If you had listened, you would have profited from the rally that followed. Now, after three months, history is repeating itself. 

    Edwards Lifesciences is a medical device manufacturer and holds a monopoly-like position in the U.S. for its Transcatheter Heart Valve (THV) called more »

  • A Board Member Bet $1.1 Million on This Stock

    By Meena Krishnamsetty - March 18, 2013 | Tickers: DXCM, HAE, HRC, MDT

    According to a Form 4 filed with the SEC, Jay Skyler of DexCom (NASDAQ: DXCM) directly purchased 70,000 shares of stock on March 11 at an average price of $15.50 per share. Between his direct holdings and his trust, he now owns over 250,000 shares of the stock (his family owns another 20,000 shares), so this was a significant percentage increase in his holdings. Studies show more »

  • Insider Buys in This Fast Growing but Loss Generating Company

    By Anh HOANG - March 18, 2013 | Tickers: BSX, DXCM, MDT

    Recently, Dr. Jay Skyler, a director of DexCom (NASDAQ: DXCM), spent nearly $1.1 million to buy 70,000 shares of the company at around $15.50 per share. Since Nov. 2011, DexCom’s share price has experienced a significant rise, from around $7 per share to $17 per share. Should investors be bullish about DexCom following its huge insider buy? Let’s find out.

    A glucose monitoring business

    DexCom more »

  • Billionaire Ray Dalio’s New Stock Picks for 2013

    By Meena Krishnamsetty - March 14, 2013 | Tickers: INTC, MAR, MDT, PG, GT

    During his tenure as CEO of Bridgewater Associates, Ray Dalio was required by the SEC to disclose his fund’s positions every quarter. Although he has since stepped down (though is still contributing as a mentor), the fund continues to meet these filing obligations. The public documents can be accessed and researched by anyone, and we have done our own due diligence to see how the fund manipulated its $9 more »

  • How the ACA’s Tax Provisions Affect the Medical Device Sector

    By Kyle Colona - March 13, 2013 | Tickers: JNJ, MDT, STJ

    This article is brief look at the medical device excise tax under the Affordable Care Act and its affect on medical device companies.

    What is the Medical Device Excise Tax?

    The $20 billion tax went into play on January 1. That figure is based on a 2.3 percent tax being levied on the total revenues of a medical device company whether or not the outfit generates a profit. According more »

  • Page 1 of 5